Bactiguard Holding Valuation

Q: What is the Fair Price of BACTI B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BACTI B (SEK33.4) is trading below our estimate of [[fair value]] (SEK59.78)

Is BACTI B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BACTI B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BACTI B (SEK33.4) is trading below our estimate of fair value (SEK59.78)

Significantly Below Fair Value: BACTI B is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BACTI B?

Key metric: As BACTI B is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BACTI B. This is calculated by dividing BACTI B's market cap by their current revenue.
What is BACTI B's PS Ratio?
PS Ratio	4.9x
Sales	SEK 236.57m
Market Cap	SEK 1.17b

BACTI B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.5x
Enterprise Value/EBITDA	-35.6x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BACTI B's PS Ratio compare to its peers?

The above table shows the PS ratio for BACTI B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.1x
OSSD OssDsign	6.1x	24.9%	SEK 771.5m
BIOWKS Bio-Works Technologies	1.8x	n/a	SEK 68.6m
XVIVO Xvivo Perfusion	19x	29.4%	SEK 14.2b
VIMIAN Vimian Group	5.5x	13.3%	SEK 22.6b
BACTI B Bactiguard Holding	4.9x	7.2%	SEK 1.2b

Price-To-Sales vs Peers: BACTI B is good value based on its Price-To-Sales Ratio (4.9x) compared to the peer average (8.1x).

Price to Sales Ratio vs Industry

How does BACTI B's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

12 Companies	Price / Sales	Estimated Growth	Market Cap
ARJO B Arjo	0.8x	3.6%	US$837.96m
CARE Careium	0.8x	10.2%	US$65.04m
BOUL Boule Diagnostics	0.5x	5.6%	US$24.11m
ARCOMA Arcoma	0.8x	8.3%	US$12.68m

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BACTI B is expensive based on its Price-To-Sales Ratio (4.9x) compared to the Swedish Medical Equipment industry average (4.8x).

Price to Sales Ratio vs Fair Ratio

What is BACTI B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BACTI B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	4.9x
Fair PS Ratio	4.1x

Price-To-Sales vs Fair Ratio: BACTI B is expensive based on its Price-To-Sales Ratio (4.9x) compared to the estimated Fair Price-To-Sales Ratio (4.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Arcoma

SEK 138.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 10.50

-2.3%

42.9%

Dignitana

SEK 85.4m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.06

-1.9%

-49.5%

Mentice

SEK 529.3m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 20.70

-17.5%

-50.7%